{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:36:58Z","timestamp":1791423418049,"version":"4.3.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI136618"],"award-info":[{"award-number":["AI136618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought to determine scenarios in which doravirine would retain activity against isolates from ART-na\u00efve persons with transmitted drug resistance (TDR) and to identify gaps in available doravirine susceptibility data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed published\n                      <jats:italic>in vitro<\/jats:italic>\n                      doravirine susceptibility data and applied the results to 42,535 RT sequences from ART-na\u00efve persons published between 2017 and 2021. NNRTI drug resistance mutations (DRMs) were defined as those with a Stanford HIV Drug Resistance Database doravirine penalty score either alone or in combination with other mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>V106A, Y188L, F227C\/L, M230L, and Y318F were associated with the greatest reductions in doravirine susceptibility. However, several NNRTI DRMs and DRM combinations lacking these canonical resistance mutations had\u2009&gt;\u2009tenfold reduced susceptibility including G190E, one isolate with G190S, three isolates with L100I\u2009+\u2009K103N, one isolate with K103N\u2009+\u2009P225H, and isolates with L100I\u2009+\u2009K103N\u2009+\u2009V108I and K101E\u2009+\u2009Y181C\u2009+\u2009G190A. Of the 42,535 ART-na\u00efve sequences, 3,374 (7.9%) contained a NNRTI DRM of which 2,788 (82.6%) contained 1 DRM (n\u2009=\u200933 distinct mutations), 426 (12.6%) contained 2 DRMs (79 distinct pairs of mutations), and 143 (4.2%) contained\u2009\u2265\u20093 DRMs (86 distinct mutation patterns). Among the 2,788 sequences with one DRM, 112 (4.0%) were associated with\u2009\u2265\u20093.0-fold reduced doravirine susceptibility while 2,625 (94.2%) were associated with\u2009&lt;\u20093.0-fold reduced susceptibility. Data were not available for individual NNRTI DRMs in 51 sequences (1.8%). Among the 426 sequences with two NNRTI DRMs, 180 (42.3%) were associated with\u2009\u2265\u20093.0 fold reduced doravirine susceptibility while just 32 (7.5%) had\u2009&lt;\u20093.0 fold reduced susceptibility. Data were not available for 214 (50.2%) sequences containing two NNRTI DRMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>First-line therapy containing doravirine plus two NRTIs is expected to be effective in treating most persons with TDR as more than 80% of TDR sequences had a single NNRTI DRM and as more than 90% with a single DRM were expected to be susceptible to doravirine. However, caution is required for the use of doravirine in persons with more than one NNRTI DRM even if none of the DRMs are canonical doravirine-resistance mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-023-00503-5","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:02:56Z","timestamp":1675728176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance"],"prefix":"10.1186","volume":"20","author":[{"given":"Soo-Yon","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Schapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Saladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"503_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","volume":"68","author":"C Orkin","year":"2019","unstructured":"Orkin C, Squires KE, Molina J-M, Sax PE, Wong W-W, Sussmann O, et al. Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68:535\u201344.","journal-title":"Clin Infect Dis"},{"key":"503_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/cid\/ciaa822","volume":"73","author":"C Orkin","year":"2021","unstructured":"Orkin C, Squires KE, Molina J-M, Sax PE, Sussmann O, Lin G, et al. Doravirine\/lamivudine\/tenofovir disoproxil fumarate (TDF) versus efavirenz\/emtricitabine\/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial. Clin Infect Dis. 2021;73:33\u201342.","journal-title":"Clin Infect Dis"},{"key":"503_CR3","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","volume":"7","author":"J-M Molina","year":"2020","unstructured":"Molina J-M, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020;7:e16-26.","journal-title":"Lancet HIV"},{"key":"503_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","volume":"87","author":"P Kumar","year":"2021","unstructured":"Kumar P, Johnson M, Molina J-M, Rizzardini G, Cahn P, Bickel M, et al. Brief report: switching to DOR\/3TC\/TDF maintains HIV-1 Virologic suppression through week 144 in the Drive-SHIFT trial. J Acquir Immune Defic Syndr. 2021;87:801\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"503_CR5","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/QAI.0000000000002153","volume":"82","author":"A Wong","year":"2019","unstructured":"Wong A, Goldstein D, Mallolas J, DeJesus E, Johnson M, Molina J-M, et al. Efficacy and safety of doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) in treatment-naive adults with HIV-1 and transmitted nonnucleoside reverse transcriptase inhibitor resistance mutations. J Acquir Immune Defic Syndr. 2019;82:e47\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"503_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25706","volume":"24","author":"K Steegen","year":"2021","unstructured":"Steegen K, Moorhouse M, Wensing AM, Venter WD, Hans L. Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa. J Int AIDS Soc. 2021;24: e25706.","journal-title":"J Int AIDS Soc"},{"key":"503_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/AAC.04201-14","volume":"59","author":"M Feng","year":"2015","unstructured":"Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai M-T. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59:590\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"503_CR8","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1093\/jac\/dkab126","volume":"76","author":"BG Brenner","year":"2021","unstructured":"Brenner BG, Oliveira M, Ibanescu R-I, Routy J-P, Thomas R. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir. J Antimicrob Chemother. 2021;76:2137\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"503_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","volume":"85","author":"EA Martin","year":"2020","unstructured":"Martin EA, Lai M-T, Ngo W, Feng M, Graham D, Hazuda DJ, et al. Review of doravirine resistance patterns identified in participants during clinical development. J Acquir Immune Defic Syndr. 2020;85:635\u201342.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"503_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01216-21","volume":"65","author":"E Asante-Appiah","year":"2021","unstructured":"Asante-Appiah E, Lai J, Wan H, Yang D, Martin EA, Sklar P, et al. Impact of HIV-1 resistance-associated mutations on susceptibility to doravirine: analysis of real-world clinical isolates. Antimicrob Agents Chemother. 2021;65: e0121621.","journal-title":"Antimicrob Agents Chemother"},{"key":"503_CR11","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1128\/AAC.02650-15","volume":"60","author":"M Feng","year":"2016","unstructured":"Feng M, Sachs NA, Xu M, Grobler J, Blair W, Hazuda DJ, et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016;60:2241\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"503_CR12","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1128\/AAC.02403-13","volume":"58","author":"M-T Lai","year":"2014","unstructured":"Lai M-T, Feng M, Falgueyret J-P, Tawa P, Witmer M, DiStefano D, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58:1652\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"503_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/QAI.0000000000001031","volume":"72","author":"SJ Smith","year":"2016","unstructured":"Smith SJ, Pauly GT, Akram A, Melody K, Ambrose Z, Schneider JP, et al. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. JAIDS J Acqui Immune Defic Syndr. 2016;72:485\u201391.","journal-title":"JAIDS J Acqui Immune Defic Syndr"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jac\/dkaa401","volume":"76","author":"F Saladini","year":"2021","unstructured":"Saladini F, Giammarino F, Hosseini BA, Giannini A, Boccuto A, Dragoni F, et al. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. J Antimicrob Chemother. 2021;76:130\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"503_CR15","doi-asserted-by":"publisher","first-page":"F41","DOI":"10.1097\/00002030-200210180-00002","volume":"16","author":"JM Whitcomb","year":"2002","unstructured":"Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002;16:F41.","journal-title":"AIDS"},{"key":"503_CR16","first-page":"437","volume":"48","author":"NT Parkin","year":"2004","unstructured":"Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1 antimicrobial agents and chemotherapy. Am SocMicrobiol. 2004;48:437\u201343.","journal-title":"Am SocMicrobiol"},{"key":"503_CR17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","volume":"58","author":"A Boyle","year":"2019","unstructured":"Boyle A, Moss CE, Marzolini C, Khoo S. Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine. Clin Pharmacokinet. 2019;58:1553\u201365.","journal-title":"Clin Pharmacokinet"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00503-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-023-00503-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00503-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:15:27Z","timestamp":1675728927000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-023-00503-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/s12981-023-00503-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1976150\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MZ received grants for research activities from Gilead Sciences, Merck Sharp and Dohme, Theratechnologies and ViiV Healthcare and personal fees for advisory boards\u00a0and training activities from Gilead Sciences, GlaxoSmithKline, Merck Sharp and Dohme, Theratechnologies and ViiV Healthcare outside the submitted work. RWS received personal fees for advisory boards and training activities from Gilead Sciences and GlaxoSmithKline.\u00a0We declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}